My friend has metastatic castrate-resistant PCa. He failed Lupron after two years, then had a good 14 month run on Zytiga before it failed, then a couple months ago entered the TRANSFORMER trial (compares Xtandi to BAT). He was randomized to the Xtandi arm, and has been on it for about
Last night, he reported his PSA has gone up from 47 a month or two ago to 64 now, so it seems the Xtandi isn't actually working. He says he'll meet with his oncologist in the next couple of weeks. It's likely they'll cross him over to the BAT arm, allowed by the trial's design. I'm going to talk to him, since I think he's had some symptoms of bone pain from mets in his femur already, and I know that's a significant issue against trying the high-testosterone BAT cycle. He may want to do it anyway, I don't know.
[Edit: Upon rereading, a "high-testosterone BAT cycle" sounds like a blast - I gotta get me one of those!
He isn't one to do much research on his own. I should know this from all the threads here, but is there anything new after failing both of the 2nd line hormonal therapies? Usually it seems docetaxel is next. I did find this article, which I plan to share with him:Drugs That Offer a Survival Advantage for Men With Bone Metastases Resulting From Castration-Resistant Prostate Cancer
He's rather distraught about
the whole thing, as you can imagine. His first grandchild is due in August, and he's said he wants to be around long enough for the little one to remember him (4-5 years old?). Kind of breaks my heart, since with mCRPC this far along that's pretty unlikely. Possible, but low probability.
This disease really sucks.
Bx: 6/12 pos, G9=5+4 (80%, 60%), 4+5 (2@100%, 80%, 10%), PNI+
cT3a (3T mpMRI: Bilateral EPE, NVB+, SV-, LN-)
Date PSA fPSA
9/12 4.1 15%
3/13 5.2 12% PCA3=31
IGRT by IMRT, 44 done 8/28/13: 50.4 Gy pelvic nodes, 79.2 Gy prostate
ADT2 3 yrs: Lupron/Casodex, ended 3/16
PSA <0.1 : 8/13 - 5/16;
rising - 0.2-8/16, 0.5-12/16, 0.7-3/17, 0.8-5/17, TBD-7/17
Post Edited (Redwing57) : 5/24/2017 7:33:19 AM (GMT-6)